Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | CPT1A | P50416 | 1/20 | 0.45 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1340672 | 0.92 | ALDH1A1 (0.51) | KDM4EALDH1A1HPGDHSD17B10L3MBTL1 | |
| SCHEMBL1340956 | 0.92 | L3MBTL1 (0.47) | KDM4EALDH1A1L3MBTL1SMN1; SMN2MAPT | |
| SCHEMBL1340640 | 0.90 | L3MBTL1 (0.49) | KDM4EALDH1A1L3MBTL1SMN1; SMN2MAPT | |
| SCHEMBL1340965 | 0.89 | L3MBTL1 (0.46) | KDM4EALDH1A1HPGDHSD17B10L3MBTL1 | |
| SCHEMBL1341104 | 0.89 | MAPT (0.48) | KDM4EALDH1A1HPGDHSD17B10L3MBTL1 | |
| SCHEMBL1341833 | 0.88 | L3MBTL1 (0.47) | KDM4EL3MBTL1SMN1; SMN2MAPTGAA | |
| SCHEMBL1340600 | 0.88 | L3MBTL1 (0.47) | KDM4EL3MBTL1SMN1; SMN2GAA | |
| SCHEMBL1340895 | 0.86 | MEN1 (0.46) | L3MBTL1SMN1; SMN2MAPTMEN1HTT | |
| SCHEMBL1340919 | 0.85 | MEN1 (0.41) | KDM4ESMN1; SMN2MAPTMEN1HTT | |
| SCHEMBL22075438 | 0.84 | MEN1 (0.43) | SMN1; SMN2MAPTMEN1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183783-A1 | Aryl carbonyl derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2006-08-17 | — | — | US | claimed |
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2004-06-24 | — | — | US | claimed |
| US-20200188394-A1 | TREATMENT OF LIVER DISEASE | UNIVERSITY OF NEWCASTLE UPON TYNE (GB) | 2020-06-18 | — | — | US | disclosed |
| US-RE45670-E1 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2015-09-15 | — | — | US | disclosed |
| US-RE45670-E1 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2015-09-15 | — | — | US | disclosed |
| EP-1531815-B1 | GLUCOKINASE ACTIVATORS | NOVO NORDISK AS (DK) | 2014-09-24 | — | — | EP | disclosed |
| EP-2471533-A1 | Aryl carbonyl derivatives as therapeutic agents | Novo Nordisk A/S (DK) | 2012-07-04 | — | — | EP | disclosed |
| EP-2471533-A1 | Aryl carbonyl derivatives as therapeutic agents | Novo Nordisk A/S (DK) | 2012-07-04 | — | — | EP | disclosed |
| US-20110301158-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | NOVO NORDISK A/S (DK) | 2011-12-08 | — | — | US | disclosed |
| US-20110301158-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | NOVO NORDISK A/S (DK) | 2011-12-08 | — | — | US | disclosed |
| US-8063081-B2 | N-(2-Phenoxyphenyl)-N'-(thiazol-2-yl)urea; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase | NOVO NORDISK A/S (DK) | 2011-11-22 | — | — | US | disclosed |
| US-20080119454-A1 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2008-05-22 | — | — | US | disclosed |
| US-20080119454-A1 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2008-05-22 | — | — | US | disclosed |
| US-20080119455-A1 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2008-05-22 | — | — | US | disclosed |
| US-20080119455-A1 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2008-05-22 | — | — | US | disclosed |
| US-20080119455-A1 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2008-05-22 | — | — | US | disclosed |
| US-20060183783-A1 | Aryl carbonyl derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2006-08-17 | — | — | US | disclosed |
| EP-1531815-A1 | GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2005-05-25 | — | — | EP | disclosed |
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2004-06-24 | — | — | US | disclosed |
| WO-2004002481-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | NOVO NORDISK A/S (DK) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301158-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | GCK, GCKR, PDK2 | KDM4E 992/4885ALDH1A1 192/4885HPGD 597/4885 |
| US-20080119455-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | KDM4E 992/4885ALDH1A1 192/4885HPGD 597/4885 |
| US-20060183783-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, PDK3, PDK4 | KDM4E 1420/4885ALDH1A1 148/4885HPGD 374/4885 |
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | KDM4E 992/4885ALDH1A1 192/4885HPGD 597/4885 |
| US-20080119454-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | KDM4E 992/4885ALDH1A1 192/4885HPGD 597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.